BetterLife Pharma Inc. announced that a joint application to the Mitacs Accelerate program, in collaboration with Dr. Argel Aguilar-Valles at Carleton University (Carleton) Department of Neuroscience, was successfully funded for research into the anti-depressant effects and mechanism of action ("MOA") of BETR-001 in preclinical models of depression. BETR-001 is a second-generation Lysergic Acid Diethylamide ("LSD") derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0962 USD | +3.44% | +16.04% | +100.42% |
03/05 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
01/05 | BetterLife Pharma Advances IND-enabling Studies For BETR-001 | MT |
1st Jan change | Capi. | |
---|---|---|
+100.42% | 10.79M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies